TY  - JOUR
AU  - Fernández, Laura
AU  - Solana, Jose Carlos
AU  - Sánchez, Carmen
AU  - Jiménez Martínez, María de los Ángeles
AU  - Requena, Jose M.
AU  - Coler, Rhea
AU  - Reed, Steven
AU  - Valenzuela, Jesús 
AU  - Kamhawi, Shaden
AU  - Oliveira, Fabiano
AU  - Fichera, Epifanio
AU  - Glueck, Reinhard
AU  - Bottazzi, Maria Elena
AU  - Gupta, Gaurav
AU  - Cecilio, Pedro
AU  - Pérez-Cabezas, Begoña
AU  - Cordeiro-da-Silva, Anabela
AU  - Gradoni, Luigi
AU  - Carrillo, Eugenia
AU  - Moreno Gonzalo, Javier
PY  - 2021
DO  - 10.3390/microorganisms9112253
UR  - https://hdl.handle.net/20.500.14352/95694
T2  - Microorganisms
AB  - Visceral leishmaniasis (VL) is the most severe clinical form of leishmaniasis, fatal if untreated. Vaccination is the most cost-effective approach to disease control; however, to date, no vaccines against human VL have been made available. This work...
LA  - eng
PB  - MDPI
KW  - Leishmaniasis
KW  - Hamster
KW  - Vaccine
KW  - Virosomes
KW  - KMP11
KW  - LEISH-F3
KW  - LJL143
KW  - GLA-SE
TI  - Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE Adjuvant
TY  - journal article
VL  - 9
ER  -